Advanced BioMedical Technologies (ABMT) Stock Statistics & Valuation Metrics
Total Valuation
Advanced BioMedical Technologies has a market cap or net worth of $50.00K. The enterprise value is $6.86T.
- Market Cap
- $50.00K
- Enterprise Value
- $6.86T
Share Statistics
Advanced BioMedical Technologies has 70,904,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 70,904,850
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Advanced BioMedical Technologies’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 15.99%.
- Return on Equity (ROE)
- 0.06
- Return on Assets (ROA)
- -1.30
- Return on Invested Capital (ROIC)
- 15.99%
- Return on Capital Employed (ROCE)
- 0.02
- Revenue Per Employee
- 15.94K
- Profits Per Employee
- -30.32K
- Employee Count
- 17
- Asset Turnover
- 0.68
- Inventory Turnover
- 0.20
Valuation Ratios
The current PE Ratio of Advanced BioMedical Technologies is -0.07. Advanced BioMedical Technologies’s PEG ratio is -0.00.
- PE Ratio
- -0.07
- PS Ratio
- 0.18
- PB Ratio
- -0.00
- Price to FCF
- -0.07
- Price to Operating Cash Flow
- -0.05
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Advanced BioMedical Technologies had revenue of 270.99K and earned -515.49K in profits. Earnings per share was -0.01.
- Revenue
- 270.99K
- Gross Profit
- 221.88K
- Operating Income
- -179.88K
- Pretax Income
- -515.49K
- Net Income
- -515.49K
- EBITDA
- -166.01K
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -626.35K and capital expenditures 272, giving a free cash flow of -626.08K billion.
- Operating Cash Flow
- -626.35K
- Free Cash Flow
- -626.08K
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Advanced BioMedical Technologies pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1469.06%
- Earnings Yield
- -1460.18%
Stock Price Statistics
- Beta
- 0.64
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.04
- 200-Day Moving Average
- 0.04
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Advanced BioMedical Technologies as a current ratio of 0.04, with Debt / Equity ratio of -85.82%
- Current Ratio
- 0.04
- Quick Ratio
- 0.01
- Debt to Market Cap
- 1.93
- Net Debt to EBITDA
- -41.00
- Interest Coverage Ratio
- -0.54
Taxes
In the past 12 months, Advanced BioMedical Technologies has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Advanced BioMedical Technologies EV to EBITDA ratio is -41.30, with an EV/FCF ratio of -9.33.
- EV to Sales
- 25.30
- EV to EBITDA
- -41.30
- EV to Free Cash Flow
- -9.33
- EV to Operating Cash Flow
- -9.33
Balance Sheet
Advanced BioMedical Technologies has $5,701.00 in cash and marketable securities with $7.09M in debt, giving a net cash position of -$7.09M billion.
- Cash & Marketable Securities
- $5,701.00
- Total Debt
- $7.09M
- Net Cash
- -$7.09M
- Net Cash Per Share
- -$0.10
- Tangible Book Value Per Share
- -$0.12
Margins
Gross margin is 81.88%, with operating margin of -66.38%, and net profit margin of -190.22%.
- Gross Margin
- 81.88%
- Operating Margin
- -66.38%
- Pretax Margin
- -190.22%
- Net Profit Margin
- -190.22%
- EBITDA Margin
- -61.26%
- EBIT Margin
- -68.23%
Analyst Forecast
The average price target for Advanced BioMedical Technologies is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
